Surveillance Study in Europe and Brazil on Clinical Aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): Implications for Empiric Therapy

Kurt G. Naber, Giancarlo Schito, Henry Botto, Juan Palou, Teresita Mazzei

Research output: Contribution to journalArticleResearchpeer-review

252 Citations (Scopus)

Abstract

Background: Uncomplicated cystitis in females is among the most frequent infections in community. Objective: To determine clinical aspects, epidemiology, and antimicrobial susceptibility of uropathogens. Intervention: Patients were investigated clinically and with urinalysis and urine culture. Measurements: This survey started in 2003 and ended in 2006 including 68 centres in nine European countries and in Brazil. Female patients between 18 and 65 yr with symptoms of uncomplicated cystitis were consecutively enrolled and clinically evaluated. Uropathogens were identified and their susceptibility tested for nine antimicrobials. Results and limitations: Clinical data of 4264 eligible patients were analysed. A positive urine culture was found in 74.6%. Within the 3018 pathogens, Escherichia coli (E. coli) was most frequent (76.7%), followed by Enterococcus faecalis (4.0%), Staphylococcus saprophyticus (3.6%), Klebsiella pneumoniae (3.5%), and Proteus mirabilis (3.5%). E. coli showed the highest rate of susceptibility to fosfomycin (98.1%) followed by mecillinam (95.8%), nitrofurantoin (95.2%), and ciprofloxacin (91.8%). The lowest rate was found for ampicillin (45.1%). For the total spectrum the order was fosfomycin (96.4%), mecillinam (95.9%), ciprofloxacin (90.3%), and nitrofurantoin (87.0%). In all countries a susceptibility rate to E. coli above 90% was found only for fosfomycin, mecillinam, and nitrofurantoin. The susceptibility rates varied significantly from country to country (p < 0.0001), except for fosfomycin, mecillinam, and nitrofurantoin. Conclusions: Despite wide cross-country variability of bacterial susceptibility/resistance rates to the other antimicrobials tested, fosfomycin, mecillinam, and nitrofurantoin have preserved their in vitro activity in all countries investigated. They may represent good options for the empiric therapy of female patients with uncomplicated cystitis. © 2008 European Association of Urology.
Original languageEnglish
Pages (from-to)1164-1178
JournalEuropean Urology
Volume54
Issue number5
DOIs
Publication statusPublished - 1 Nov 2008

Keywords

  • Ampicillin
  • Antimicrobial resistance
  • Ciprofloxacin
  • Cystitis
  • Fosfomycin trometanol
  • Nitrofurantoin
  • Pivmecillinam
  • Treatment
  • Uncomplicated urinary tract infection
  • Uropathogens

Fingerprint Dive into the research topics of 'Surveillance Study in Europe and Brazil on Clinical Aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): Implications for Empiric Therapy'. Together they form a unique fingerprint.

Cite this